collection
MENU ▼
Read by QxMD icon Read
search

cardiotoxicity

shared collection
97 papers 0 to 25 followers
By Elvis Amao Internal Medicine , Cardiology and infectious diseases
https://www.readbyqxmd.com/read/28710069/vitamin-c-mitigates-oxidative-nitrosative-stress-and-inflammation-in-doxorubicin-induced-cardiomyopathy
#1
Gauri Akolkar, Danielle da Silva Dias, Prathapan Ayyappan, Ashim K Bagchi, Davinder S Jassal, Vera Mc Salemi, Maria Claudia Irigoyen, Katia De Angelis, Pawan K Singal
Increase in oxidative/nitrosative stress is one of the mechanisms associated with the development of cardiotoxicity due to Doxorubicin (Dox), a potent chemotherapy drug. Previously, we reported mitigation of Dox-induced oxidative/nitrosative stress and apoptosis by Vitamin C (Vit C) in isolated cardiomyocytes. In the present in vivo study in rats, we investigated the effect of prophylactic treatment with Vit C on Dox-induced apoptosis, inflammation, oxidative/nitrosative stress, cardiac dysfunction and Vit C transporter proteins...
July 14, 2017: American Journal of Physiology. Heart and Circulatory Physiology
https://www.readbyqxmd.com/read/28718245/left-ventricular-systolic-dysfunction-predicted-by-early-troponin-i-release-after-anthracycline-based-chemotherapy-in-breast-cancer-patients
#2
Azhar Shafi, Neelam Siddiqui, Saba Imtiaz, Mansoor Ud Din Sajid
BACKGROUND: Anthracyclines are one of the most effective chemotherapeutic agents in management of Breast cancer, however Anthracycline induced cardiotoxicity remains a matter of special concern. Detection of early toxicity by use of biomarkers like Troponins has been the focus of interest in recent years. We measured Troponin I levels after chemotherapy with anthracyclines and correlated it with ECG, Echocardiography and clinical findings. METHODS: Patients with early Breast cancer eligible for chemotherapy were included in the study...
April 2017: Journal of Ayub Medical College, Abbottabad: JAMC
https://www.readbyqxmd.com/read/28646013/doxorubicin-effect-on-myocardial-metabolism-as-a-pre-requisite-for-subsequent-development-of-cardiac-toxicity-a-translational-18-f-fdg-pet-ct-observation
#3
Matteo Bauckneht, Giulia Ferrarazzo, Francesco Fiz, Silvia Morbelli, Matteo Sarocchi, Fabio Pastorino, Alberto Ghidella, Elena Pomposelli, Maurizio Miglino, Pietro Ameri, Laura Emionite, Flavia Ticconi, Eleonora Arboscello, Ambra Buschiazzo, Elena Augusta Massimelli, Salvatore Fiordoro, Anna Borra, Vanessa Cossu, Annalisa Bozzano, Adalberto Ibatici, Mirco Ponzoni, Paolo Spallarossa, Andrea Gallamini, Paolo Bruzzi, Gianmario Sambuceti, Cecilia Marini
The present translational study aimed to verify whether serial (18)F-fluoro-deoxyglucose Positron Emission Tomography/Computed Tomography (FDG-PET/CT), predicts doxorubicin cardiotoxicity. Methods: Fifteen athymic mice were treated with intravenous administration of saline (n = 5), doxorubicin 5 mg/Kg (n = 5) or doxorubicin 7.5 mg/Kg (n = 5) and submitted to dynamic microPET scan to estimate left ventricular glucose consumption (LV-MRGlu) before and after chemotherapy. Thereafter, we retrospectively identified 69 patients successfully treated with Adriamycin, Bleomycin, Vinblastine, and Dacarbazine (ABVD) regimen for Hodgkin's Disease (HD) and submitted to four consecutive FDG-PET/CT scans...
June 23, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28692525/effect-of-adjuvant-chemotherapy-on-left-ventricular-remodeling-in-women-with-newly-diagnosed-primary-breast-cancer-a-pilot-prospective-longitudinal-cardiac-magnetic-resonance-imaging-study
#4
Erick Avelar, Quynh A Truong, David Inyangetor, Ravi Marfatia, Clifford Yang, Electra Kaloudis, Susan Tannenbaum, Guido Rosito, Sheldon Litwin
PURPOSE: The aim of this study was to assess the left ventricular (LV) remodeling response to chemotherapy in low-cardiac-risk women with newly diagnosed nonmetastatic breast cancer. Cardiotoxic effects of chemotherapy are an increasing concern. To effectively interpret cardiac imaging studies performed for screening purposes in patients undergoing cancer therapy it is necessary to understand the normal changes in structure and function that may occur. METHODS: Twenty women without preexisting cardiovascular disease, of a mean age of 50 years, newly diagnosed with nonmetastatic breast cancer and treated with anthracycline or trastuzumab were prospectively enrolled and evaluated at four time points (at baseline, during chemotherapy, 2 weeks after chemotherapy, and 6 months after chemotherapy) using cardiac magnetic resonance imaging, blood samples, and a clinical questionnaire...
July 7, 2017: Journal of Thoracic Imaging
https://www.readbyqxmd.com/read/28698984/echocardiographic-evaluation-of-cardiac-function-after-cancer-chemotherapy
#5
REVIEW
Tomoko Negishi, Kazuaki Negishi
Progress in cancer therapy has led to improved prognosis of patients with cancer and thus to a continuous rise of cancer survivors. However, it has simultaneously increased cardiovascular morbidity and mortality rates due to direct and/or indirect side effects of anticancer treatment. Similar to the rapid rise of patients with adult congenital disease, the number of patients suffering or at risk of cardiotoxicity has been steeply increasing and getting an emerging issue. Among the many facets of chemotherapy-induced cardiovascular toxicity, this review attempts to summarize echocardiographic evaluation of cardiac function after cancer chemotherapy by reviewing the definition, risk factors, brief history, limitation of left ventricular ejection fraction and myocardial strain imaging, as well as the limitations of this technique...
July 11, 2017: Journal of Echocardiography
https://www.readbyqxmd.com/read/28700343/cardiotoxicity-of-trastuzumab-in-patients-with-her2-positive-gastric-cancer
#6
Ji Soo Park, Jong-Chan Youn, Chi Young Shim, Geu-Ru Hong, Choong-Kun Lee, Jee Hyung Kim, Hyung Soon Park, Su Jin Heo, Seung Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyun Cheol Chung, Seok-Min Kang, Minkyu Jung
Trastuzumab-induced cardiotoxicity (TIC) is the primary adverse event that limits the use of trastuzumab in HER2-positive breast cancer patients. However, the incidence and risk factors of TIC in HER2-positive gastric cancer are not known. Therefore, we evaluated the incidence and predictive factors of TIC in gastric cancer patients treated with trastuzumab in clinical practice. We reviewed cardiac dysfunction in HER2-positive gastric cancer patients between December 2005 and April 2015 in a prospectively-collected database that included prospective clinical trials at Yonsei Cancer Center, Republic of Korea...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28652542/therapeutic-potential-of-ghrelin-and-des-acyl-ghrelin-against-chemotherapy-induced-cardiotoxicity
#7
Miki Nonaka, Nagomi Kurebayashi, Takashi Murayama, Masami Sugihara, Kiyoshi Terawaki, Seiji Shiraishi, Kanako Miyano, Hiroshi Hosoda, Shosei Kishida, Kenji Kangawa, Takashi Sakurai, Yasuhito Uezono
Cancer was considered an incurable disease for many years; however, with the development of anticancer drugs and state-of-the art technologies, it has become curable. Cardiovascular diseases in patients with cancer or induced by cancer chemotherapy have recently become a great concern. Certain anticancer drugs and molecular targeted therapies cause cardiotoxicity, which limit the widespread implementation of cancer treatment and decrease the quality of life in cancer patients significantly. The anthracycline doxorubicin (DOX) causes cardiotoxicity...
2017: Endocrine Journal
https://www.readbyqxmd.com/read/28562342/association-between-obesity-and-trastuzumab-related-cardiac-toxicity-in-elderly-patients-with-breast-cancer
#8
Hai-Yan Wang, Bei-Bei Yin, Dan-Yan Jia, Ying-Long Hou
PURPOSE: Trastuzumab can improve the prognosis for patients with breast cancer, but its related cardiac toxicity is concerning. This study aimed to identify the risk factors associated with trastuzumab-related cardiac toxicity in elderly patients with HER2-positive breast cancer. PATIENTS AND METHODS: A total of 133 elderly (≥ 65 years) patients who were diagnosed with breast cancer between June 1, 2007, and January 31, 2016, and received trastuzumab treatment were retrospectively reviewed...
May 11, 2017: Oncotarget
https://www.readbyqxmd.com/read/28552383/transient-congenital-dilated-cardiomyopathy-after-maternal-r-chop-chemotherapy-during-pregnancy
#9
Stephanie Padberg, Inge Mick, Cornelia Frenzel, Richard Greil, Johannes Hilberath, Christof Schaefer
Pregnancy-associated diffuse large B-cell lymphoma (DLBCL) is a rare event. Experience regarding fetal effects of maternal treatment during pregnancy is limited. Cardiotoxicity is a known adverse effect of some antineoplastic agents especially of doxorubicin. We report a case of pregnancy-associated DLBCL, which was treated between gestational week 26 and 33 with three cycles of R-CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone combined with rituximab). At gestational age 34 2/7 she delivered a male infant who was admitted to neonatal care due to cardiomyopathy...
May 25, 2017: Reproductive Toxicology
https://www.readbyqxmd.com/read/28542097/genome-wide-association-and-pathway-analysis-of-left-ventricular-function-after-anthracycline-exposure-in-adults
#10
Quinn S Wells, Olivia J Veatch, Joshua P Fessel, Aron Y Joon, Rebecca T Levinson, Jonathan D Mosley, Elizabeth P Held, Chase S Lindsay, Christian M Shaffer, Peter E Weeke, Andrew M Glazer, Kevin R Bersell, Sara L Van Driest, Jason H Karnes, Marcia A Blair, Lore W Lagrone, Yan R Su, Erica A Bowton, Ziding Feng, Bonnie Ky, Daniel J Lenihan, Michael J Fisch, Joshua C Denny, Dan M Roden
BACKGROUND: Anthracyclines are important chemotherapeutic agents, but their use is limited by cardiotoxicity. Candidate gene and genome-wide studies have identified putative risk loci for overt cardiotoxicity and heart failure, but there has been no comprehensive assessment of genomic variation influencing the intermediate phenotype of anthracycline-related changes in left ventricular (LV) function. The purpose of this study was to identify genetic factors influencing changes in LV function after anthracycline chemotherapy...
July 2017: Pharmacogenetics and Genomics
https://www.readbyqxmd.com/read/28550591/cardiovascular-risk-in-survivors-of-cancer
#11
REVIEW
Henry Chen Zheng, Laura Onderko, Sanjeev A Francis
PURPOSE OF REVIEW: Survivors of childhood and adult cancers face increased risk of cardiovascular disease. We review the current evidence base and guidelines for this rapidly growing population. RECENT FINDINGS: Research continues to show that cardiovascular disease is an important cause of morbidity and mortality in cancer survivors. Cardiotoxicity related to chemotherapy and radiotherapy accounts for part of this increased risk. There is emerging evidence that cancer and cardiovascular disease share a similar biology and risk factors...
July 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28453909/cardiotoxicity-and-cardiomyopathy-in-children-and-young-adult-survivors-of-hematopoietic-stem-cell-transplant
#12
REVIEW
Seth J Rotz, Thomas D Ryan, Joel Hlavaty, Stephen A George, Javier El-Bietar, Christopher E Dandoy
Cardiomyopathy is common in long-term survivors of pediatric hematopoietic stem cell transplant (HSCT). Events occurring before and after HSCT when combined with specific insults during HSCT likely contribute to long-term risk. Strategies for detecting subclinical cardiomyopathy prior to patients developing overt heart failure are under investigation. Changes in HSCT preparative regimens and cardioprotective medications administered during chemotherapy may alter the risk for cardiomyopathy. Interventions in long-term survivors such as lifestyle modification and cardioactive medications are of increasing importance...
April 28, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/28469492/diagnostic-strategies-for-early-recognition-of-cancer-therapeutics-related-cardiac-dysfunction
#13
REVIEW
Carlos R Manrique, Michael Park, Nidhish Tiwari, Juan Carlos Plana, Mario J Garcia
Cardiovascular toxicity in the form of cardiac dysfunction continues to be an obstacle for patients with cancer. Survival and quality of life of cancer survivors are frequently affected by increased incidence of cardiovascular disease. The involvement of the cardiovascular system by primary or secondary malignancies, as well as its dysfunction secondary to the administration of antineoplastics, has led to the development of a new discipline called Cardio-Oncology, an exciting cardiology subspecialty with more questions than answers and as a result an enormous opportunity for research in the field...
2017: Clinical Medicine Insights. Cardiology
https://www.readbyqxmd.com/read/28505345/cardio-oncology-a-multidisciplinary-approach-for-detection-prevention-and-management-of-cardiac-dysfunction-in-cancer-patients
#14
Kazuko Tajiri, Kazutaka Aonuma, Ikuo Sekine
Cardiac dysfunction that develops during or after completion of cancer therapy is a growing health concern that should be addressed in a multidisciplinary setting. Cardio-oncology is a new discipline that focuses on screening, monitoring and treating cardiovascular disease during and after cancer treatment. A baseline cardiovascular risk assessment is essential. For high-risk patients, a tailored and detailed plan for cardiovascular management throughout treatment and beyond should also be established. Anthracycline and/or trastuzumab-containing chemotherapy and chest-directed radiation therapy are well known cardiotoxic cancer therapies...
May 15, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28485067/chemotherapy-related-cardiotoxicity-are-australian-practitioners-missing-the-point
#15
Rachel Conyers, Ben Costello, Anne Tripaydonis, Charlotte Burns, Louise Ludlow, Peter Lange, Paul Ekert, Francoise Mechinaud, Michael Cheung, Michelle Martin, David Elliot
BACKGROUND: It has long been established that cardiotoxicity occurs as a result of exposure to certain chemotherapeutics, particularly anthracyclines. Historically, clinicians equate cardiotoxicity with a poor prognosis, in a small percentage of patients and deem long-term surveillance as optional. Emerging evidence suggests that anthracycline cardiotoxicity (ACT) is a life-long risk with an incidence approaching 20%. METHODS: Participants were identified via the Haematology-Oncology (HO) database at the Royal Children's Hospital, Melbourne...
May 9, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28474324/role-of-imaging-in-cardio-oncology
#16
REVIEW
Erick Avelar, Caitlin R Strickland, Guido Rosito
Recent advances in cancer treatment and research have greatly improved survival rates for patients with cancer. However, many of these cancer survivors are developing cardiac disease-most commonly heart failure as a result of this treatment. Certain chemotherapeutic agents, including anthracyclines and trastuzumab, have been linked to cardiotoxicity-induced cardiomyopathy in cancer patients. It has been reported as early as during infusion and as late as several years following treatment. Radiation therapy, particularly to the left breast, has also been linked to cardiac disease...
June 2017: Current Treatment Options in Cardiovascular Medicine
https://www.readbyqxmd.com/read/28353310/the-early-variation-of-left-ventricular-twisting-function-in-patients-with-lymphoma-received-anthracycline-therapy-assessed-by-three-dimensional-speckle-tracking-echocardiography
#17
Feiyan Song, Yu Kang, Chujie Zhang, Yuchen Xu, Jing Shi, Ye Guo, Qunling Zhang, Xianhong Shu, Leilei Cheng
BACKGROUND: Anthracycline-induced cardiotoxicity remains a significant and unresolved issue in patients receiving chemotherapy. The aim of this study was to evaluate left ventricular (LV) twisting function by three-dimensional speckle tracking echocardiography (3D-STE) in patients with lymphoma after anthracycline therapy. METHODS: One hundred and one patients with newly diagnosed diffuse large B-cell lymphoma who had planned to receive anthracycline chemotherapy were enrolled...
March 29, 2017: Cardiology Journal
https://www.readbyqxmd.com/read/28379383/2d-and-3d-strain-for-detection-of-subclinical-anthracycline-cardiotoxicity-in-breast-cancer-patients-a-balance-with-feasibility
#18
Ciro Santoro, Grazia Arpino, Roberta Esposito, Maria Lembo, Immacolata Paciolla, Cinzia Cardalesi, Giovanni de Simone, Bruno Trimarco, Sabino De Placido, Maurizio Galderisi
Aims: 2D echocardiography is limited for identifying chemotherapy-related cardiotoxicity. This study compared standard echo, 2D, and 3D speckle tracking echocardiography (STE) for detection of subclinical anthracycline (ANT) cardiotoxicity in breast cancer patients. Methods and results: One-hundred consecutive breast cancer patients free of cardiac symptoms were treated by multiple protocols including ANT and cyclophosphamide and/or 5-fluorouracil for 3-4 cycles...
March 31, 2017: European Heart Journal Cardiovascular Imaging
https://www.readbyqxmd.com/read/28275118/modern-management-of-anthracycline-induced-cardiotoxicity-in-lymphoma-patients-low-occurrence-of-cardiotoxicity-with-comprehensive-assessment-and-tailored-substitution-by-nonpegylated-liposomal-doxorubicin
#19
Jacopo Olivieri, Gian Piero Perna, Caterina Bocci, Claudia Montevecchi, Attilio Olivieri, Pietro Leoni, Guido Gini
BACKGROUND: Anthracyclines (AC) are still undeniable drugs in lymphoma treatment, despite occasionally causing cardiotoxicity. Liposomal AC may reduce cardiotoxicity while retaining clinical efficacy; also, biomarker monitoring during chemotherapy allows early detection of cardiac damage, enabling strategies to prevent left ventricular ejection fraction (LVEF) deterioration. MATERIALS AND METHODS: We conducted a prospective observational trial in a real-life population of lymphoma patients, combining advanced echocardiography and biomarkers (Troponin I [TnI]) for early detection of cardiotoxicity; we applied a prespecified policy to minimize cardiotoxicity, selecting patients with higher baseline risk to replace doxorubicin with nonpegylated liposomal doxorubicin (NPLD) and starting cardioprotective treatment when subclinical cardiotoxicity was detected...
April 2017: Oncologist
https://www.readbyqxmd.com/read/28279418/advanced-heart-failure-therapies-for-cancer-therapeutics-related-cardiac-dysfunction
#20
REVIEW
Christopher M Bianco, Sadeer G Al-Kindi, Guilherme H Oliveira
End-stage heart failure in cancer survivors may result from cardiotoxic chemotherapy and/or chest radiation and require advanced therapies, including left ventricular assist devices (LVADs) and transplantation. Traditionally, such therapies have been underutilized in cancer survivors owing to lack of experience and perceived risk of cancer recurrence. Recent data from large registries, however, have shown excellent outcomes of LVADs and transplantation in cancer survivors, albeit subject to careful selection and special considerations...
April 2017: Heart Failure Clinics
label_collection
label_collection
6870
1
2
2017-03-13 09:14:49
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"